Copyright
©2007 Baishideng Publishing Group Co.
World J Gastroenterol. Jul 28, 2007; 13(28): 3836-3840
Published online Jul 28, 2007. doi: 10.3748/wjg.v13.i28.3836
Published online Jul 28, 2007. doi: 10.3748/wjg.v13.i28.3836
Table 4 Incidence of adverse events
| Lafutidine group | Lansoprazole group | P | ||
| Adverse events | Not present | 17 | 17 | NS |
| Present | 3 | 3 | ||
| Incidence of adverse events | 15.0% (3/20) | 15.0% (3/20) | ||
| Adverse events | Stomatitis | 3 | NS | |
| Diarrhea | 1 | 1 | ||
| Constipation | 1 | |||
| Throat pain | 1 | |||
| Drug rash | 1 | |||
| Taste disorder | 1 | |||
-
Citation: Hagiwara T, Kato M, Anbo T, Imamura A, Suga T, Uchida T, Fujinaga A, Nakagawa M, Nakagawa S, Shimizu Y, Yamamoto J, Takeda H, Asaka M. Improvement in symptoms after H2-receptor antagonist-based therapy for eradication of
H pylori infection. World J Gastroenterol 2007; 13(28): 3836-3840 - URL: https://www.wjgnet.com/1007-9327/full/v13/i28/3836.htm
- DOI: https://dx.doi.org/10.3748/wjg.v13.i28.3836